Sign In
Buy SNY
$43.75
-0.230 (-0.523%)
At Close: Jul 21, 2026
Pharma Stock Roundup: FDA Panel Backs Updated COVID Jabs, EU Nod for SNY, MRK Drugs
12:46pm, Thursday, 30'th Jun 2022 Zacks Investment Research
An FDA panel recommends updating COVID-19 booster shots. EU approvals for Sanofi's (SNY) two new drugs and expanded use of Merck's (MRK) Keytruda and Novartis' (NVS) Cosentyx.
Investors Need Not Be Alarmed by Drug Patent Expirations
04:02pm, Tuesday, 28'th Jun 2022
Investors who are sweating the loss of patent protection for some of Big Pharma's top-selling drugs should relax.
Sanofi (SNY) Wins Nod for Nexviadyme & Xenpozyme in Europe
02:14pm, Tuesday, 28'th Jun 2022 Zacks Investment Research
Sanofi's (SNY) Nexviadyme is approved for the treatment of both late-onset Pompe disease and infantile-onset Pompe disease. Xenpozyme is approved for non-Central Nervous System (CNS) manifestations of
Sanofi (SNY) Wins Nod for Nexviadyme & Xenpozyme in Europe
11:35am, Tuesday, 28'th Jun 2022
Sanofi's (SNY) Nexviadyme is approved for the treatment of both late-onset Pompe disease and infantile-onset Pompe disease. Xenpozyme is approved for non-Central Nervous System (CNS) manifestations of
Sanofi's Top-Selling Drug Just Snagged Another Approval From the FDA
02:23pm, Saturday, 25'th Jun 2022 The Motley Fool
Mega-blockbuster Dupixent was just given the FDA's green light to treat patients with a chronic, progressive inflammatory disease.
Why Sanofi May Be a Frontrunner in Endemic COVID-19
12:09pm, Saturday, 25'th Jun 2022 The Motley Fool
There is a promising outlook for its next generation of vaccines.
Sanofi's Top-Selling Drug Just Snagged Another Approval From the FDA
10:23am, Saturday, 25'th Jun 2022
Mega-blockbuster Dupixent was just given the FDA's green light to treat patients with a chronic, progressive inflammatory disease.
Why Sanofi May Be a Frontrunner in Endemic COVID-19
08:09am, Saturday, 25'th Jun 2022
There is a promising outlook for its next generation of vaccines.
GSK and Sanofi's Covid-19 Vaccine Could Pose a Challenge to Pfizer and Moderna
09:50am, Friday, 24'th Jun 2022
Sanofi and GSK's joint Covid-19 vaccine has finally produced data that could challenge the dominance of the Pfizer and Moderna vaccines.
Sanofi, GSK say their next-generation COVID-19 booster has 72% efficacy against omicron
08:27am, Friday, 24'th Jun 2022
Sanofi SNY, +0.38% SAN, +3.70% and GlaxoSmithKline GSK, +1.86% said Friday that their experimental bivalent COVID-19 booster had a 72% efficacy rate against omicron, and they now plan to submit the da
Sanofi-GSK's Beta-Containing COVID-19 Vaccine Shows Efficacy Against Omicron
07:45am, Friday, 24'th Jun 2022
Sanofi SA (NASDAQ: SNY) and GSK plc (NYSE: GSK) have announced positive data from their vaccine trial of adjuvanted bivalent D614 and Beta (B.1.351) vaccine candidate. "Sanofi-GSK's vaccine is
Press Release: Sanofi-GSK first to report a successful efficacy study against Omicron with COVID-19 Beta-containing vaccine
01:29am, Friday, 24'th Jun 2022
Sanofi-GSK first to report a successful efficacy study against Omicron with COVID-19 Beta-containing vaccine
Bridgewater's bearish bets on European stocks jump to $10.5 billion - Bloomberg News
09:38am, Thursday, 23'rd Jun 2022
Bridgewater Associates has raised its short position on European stocks to $10.5 billion, nearly doubling from the previous week, according to a Bloomberg News report on Thursday, in a sign the hedge
Why These 5 European Dividend Aristocrats (Some With Huge Yields) Are Incredible Q3 Buys
07:35am, Thursday, 23'rd Jun 2022
Well, that didn't last long. As we suspected, each and every market rally until the Federal Reserve completes the interest rate hike cycle likely will be met with selling as investors try to go to cas
14 Ideal June Dividend Buys From 118 Potent Picks To Profit For 2022
05:26am, Wednesday, 22'nd Jun 2022 Seeking Alpha
Any collection of stocks is clearly understood when subjected to yield-based analysis. Click here for 14 ideal June dividend buys to profit for 2022.
